DAPA MET XR 10+500MG TABLET

DAPA MET XR 10+500MG TABLET is a combination medication containing two active ingredients: DAPAGLIFLOZIN + METFORMIN. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin is a biguanide. Together, they work to manage blood sugar levels in individuals with type 2 diabetes.

Uses:

1. Type 2 Diabetes Mellitus:
   • DAPA MET XR 10+500MG TABLET is indicated for the treatment of type 2 diabetes mellitus in adults. It is typically prescribed when blood sugar levels are not adequately controlled by diet and exercise alone.

Components and Mechanism of Action:

1. Dapagliflozin:
   • Dapagliflozin works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary excretion of glucose and, consequently, lowering blood sugar levels.
2. Metformin:
   • Metformin improves the body’s response to insulin, reduces the production of glucose by the liver, and enhances the uptake of glucose by tissues, contributing to better blood sugar control.

Side Effects:

Common side effects of DAPA MET XR 10+500MG TABLET may include:

• Genital yeast infections (for dapagliflozin)
• Gastrointestinal disturbances (e.g., nausea, diarrhea) for metformin
• Urinary tract infections

Serious side effects may include:

• Lactic acidosis (for metformin)
• Hypotension (low blood pressure)
• Ketoacidosis (for dapagliflozin)

When Not to Use:

1. Type 1 Diabetes:
   • DAPA MET XR is not intended for the treatment of type 1 diabetes.
2. Hypersensitivity:
   • Individuals with a known hypersensitivity to dapagliflozin, metformin, or any components of the formulation should avoid using this medication.

Precautions and Warnings:

• Renal Impairment:
  • DAPA MET XR should be used with caution in individuals with renal impairment, as both dapagliflozin and metformin are excreted by the kidneys.
• Lactic Acidosis:
  • Metformin may increase the risk of lactic acidosis, particularly in patients with conditions such as renal impairment or congestive heart failure.
• Dehydration:
  • Dapagliflozin may lead to dehydration, especially in elderly patients or those with low blood volume.

Dosage and Administration:

• The dosage of DAPA MET XR should be individualized based on the patient’s condition and response to treatment. It is typically taken orally, with or without food.

Patients should follow their healthcare provider’s instructions, monitor for any unusual symptoms, and report side effects promptly. This information is not exhaustive, and healthcare providers should refer to the prescribing information for a comprehensive understanding of the medication.